ReviewNature reviews. Microbiology2023
Translating eco-evolutionary biology into therapy to tackle antibiotic resistance.
Review in Nature reviews. Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the oral resistome: a systematic review.Journal of medical microbiology · 2024Pooled it
- A network dynamical simulation model for the study of antibiotic resistance in microbial communities.Gut microbes · 2026Article
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Carbapenem-resistance oprD mutations reshape Pseudomonas aeruginosa host-pathogen interactions during infection.Nature communications · 2026Article
- Mitochondrial heterogeneity drives the evolution of fungicide resistance inScience advances · 2026Article
- Cooperative antibiotic resistance in bacteria: beyond biofilms.Frontiers in microbiology · 2026Review
- Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa.Nature communications · 2025Article
- Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.Nature communications · 2025Article
- Exploring the effect of sequential antibiotic exposure in resistantMicrobiology spectrum · 2025Article
- Refuse in order to resist: metabolic bottlenecks reduce antibiotic susceptibility.Molecular systems biology · 2025Article
- Towards next-generation treatment options to combat Plasmodium falciparum malaria.Nature reviews. Microbiology · 2025Review
- Biomolecular Microneedle Initiates FeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A streamlined method to determine the antibiotic resistance of plaque-forming predatory bacteria.Frontiers in microbiology · 2025Article
- Tobramycin-resistant small colony variant mutant ofVirulence · 2024Article
- Unraveling the genomic diversity of the Pseudomonas putida group: exploring taxonomy, core pangenome, and antibiotic resistance mechanisms.FEMS microbiology reviews · 2024Review
- Preserving the efficacy of antibiotics to tackle antibiotic resistance.Microbial biotechnology · 2024Review
- Role of bacterial multidrug efflux pumps during infection.World journal of microbiology & biotechnology · 2024Review
- Fitness trade-offs of multidrug efflux pumps inApplied and environmental microbiology · 2024Article
- Genomic surveillance for antimicrobial resistance - a One Health perspective.Nature reviews. Genetics · 2024Review
- Navigating collateral sensitivity: insights into the mechanisms and applications of antibiotic resistance trade-offs.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is currently one of the most important public health problems. The golden age of antibiotic discovery ended decades ago, and new approaches are urgently needed. Therefore, preserving the efficacy of the antibiotics currently in use and developing compounds and strategies that specifically target antibiotic-resistant pathogens is critical. The identification of robust trends of antibiotic resistance evolution and of its associated trade-offs, such as collateral sensitivity or fitness costs, is invaluable for the design of rational evolution-based, ecology-based treatment approaches. In this Review, we discuss these evolutionary trade-offs and how such knowledge can aid in informing combination or alternating antibiotic therapies against bacterial infections. In addition, we discuss how targeting bacterial metabolism can enhance drug activity and impair antibiotic resistance evolution. Finally, we explore how an improved understanding of the original physiological function of antibiotic resistance determinants, which have evolved to reach clinical resistance after a process of historical contingency, may help to tackle antibiotic resistance.
Indexed as
Identifiers
37208461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.